Cost-effectiveness analysis of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer with EGFR mutations in China

Y Shu, Q Zhang, X He, L Chen - Cancer Management and …, 2021 - Taylor & Francis
Objective The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …
被引用次数：7 相关文章

Cost Effectiveness Analysis Of Gefitinib Plus Chemotherapy Versus Gefitinib Alone For Advanced Non-Small-Cell Lung Cancer With EGFR Mutations In China

L Chen, J Meana, B Shen - 2021 - sciforum.net
Objective: The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non–small-cell lung (NSCLC) …

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Y Shu, Q Zhang, X He, L Chen - Cancer management …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.

Y Shu, Q Zhang, X He, L Chen - Cancer Management and Research, 2021 - europepmc.org
Objective The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Y Shu, Q Zhang, X He, L Chen - Cancer Management and …, 2021 - search.proquest.com
Objective: The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.

Y Shu, Q Zhang, X He, L Chen - Cancer Management and Research, 2021 - go.gale.com
Objective: The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …
[HTML] nih.gov

[HTML][HTML] Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Y Shu, Q Zhang, X He, L Chen - Cancer Management and …, 2021 - ncbi.nlm.nih.gov
Objective The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China

Y Shu, Q Zhang, X He, L Chen - Cancer Management and Research, 2021 - dovepress.com
Objective: The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …